Alum Zoom with Jacob Jacobsen, PhD, CSO, Evecxia Therapeutics

Evecxia Inc is a biopharmaceutical company focused on the treatment of neuropsychiatric diseases. Dr. Jacobsen directs the development of EVX-101, the Company's lead clinical-stage product candidate for the adjunctive treatment of depression in patients not achieving an adequate response to traditional SSRI/SNRI antidepressants. While a postdoc in Dr. Marc Caron's lab in the Department of Cell Biology, Dr. Jacobsen built the 5-hydroxytryptophan slow-release (5-HTP SR) scientific and technical rationale undergirding EVX-101. Dr. Jacobsen earned his PhD in Neuropharmacology at The University of Copenhagen. Drs. Jacobsen and Caron are co-founders of Evecxia.

In addition to discussing his work, Jacob will tell us about the open PhD-level positions at Evecxia Therapeutics.

5 Questions:

1. Could you tell us about your background?
2. How did you get your job at your organization?
3. What's a typical day like at your organization, pre- and post-COVID?
4. What can postdocs and students who would like to work in this field (or explore it further) do to prepare?
5. What is the employment outlook for this field, given the COVID crisis? (please note that the answer to this question may be "We don't know yet.")
6. Bonus 6th question: Can you tell us about the open PhD-level positions at Evecxia Therapeutics ?